Advertisement
UK markets open in 59 minutes

  • NIKKEI 225

    38,147.39
    -54.98 (-0.14%)
     

  • HANG SENG

    18,537.28
    +223.42 (+1.22%)
     

  • CRUDE OIL

    79.38
    +0.39 (+0.49%)
     

  • GOLD FUTURES

    2,322.90
    +0.60 (+0.03%)
     

  • DOW

    39,056.39
    +172.13 (+0.44%)
     

  • Bitcoin GBP

    49,310.86
    -812.20 (-1.62%)
     

  • CMC Crypto 200

    1,312.37
    +12.27 (+0.94%)
     

  • NASDAQ Composite

    16,302.76
    -29.80 (-0.18%)
     

  • UK FTSE All Share

    4,544.24
    +21.25 (+0.47%)
     
Money:

How to make a tax-free income

Tips for making money that won't be taxed

AstraZeneca's Acquisition of Alexion Is Nearly a Done Deal, But Is It a Good Deal?

Keith Speights and Brian Orelli, PhD, The Motley Fool
·2-min read

AstraZeneca (NASDAQ: AZN) hopes to soon close its planned acquisition of Alexion Pharmaceuticals (NASDAQ: ALXN). In this Motley Fool Live video recorded on July 7, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not the Alexion acquisition is a good deal for AstraZeneca. Keith Speights: AstraZeneca has experienced multiple problems with the launch of its COVID-19 vaccine and we're not going to get into all of those problems but there's more news non-COVID related for AstraZeneca now.

Continue reading